Announcement • Aug 05
GlucoTrack, Inc. announced that it expects to receive $5.5 million in funding GlucoTrack, Inc entered into a definitive agreement with institutional investors for a private placement to issue 2,666,666 units at an issue price of $0.75 for the proceeds of $1,999,999.5 and convertible debt for the proceeds of $3,500,000 on August 5, 2026. Unit comprised of one share of common stock (or equivalent) and one five-year warrant with an exercise price of $1.50 per share. Announcement • Jul 20
GlucoTrack, Inc., Annual General Meeting, Aug 18, 2026 GlucoTrack, Inc., Annual General Meeting, Aug 18, 2026. Announcement • Jul 16
Lokahi Therapeutics Inc. entered into an Agreement and Plan of Merger to acquire GlucoTrack, Inc. (NasdaqCM:GCTK) in a reverse merger transaction. Lokahi Therapeutics Inc. entered into an Agreement and Plan of Merger to acquire GlucoTrack, Inc. (NasdaqCM:GCTK) in a reverse merger transaction on July 14, 2026. The transaction is structured such that Lokahi Therapeutics becomes the operating and controlling business of the combined company. In connection with the closing, Lokahi Therapeutics securityholders received a combination of Glucotrack common stock and convertible preferred stock. Upon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements, the preferred stock is expected to convert into common equity, resulting in Lokahi Therapeutics securityholders holding approximately 90% of the combined company on a fully diluted basis, subject to transaction-related financing and customary adjustments. The transaction is supported by a planned private placement financing designed to strengthen the combined company’s capital position and support near-term execution.
Erik Emerson has been appointed Chief Executive Officer of the combined company. Paul Goode will serve as Chief Technical Officer of the combined company and Chief Executive Officer of the CBGM subsidiary. As contemplated in the Merger Agreement, GlucoTrack was required to take all actions necessary to effect, as of the Effective Time: (i) the resignation of Paul V. Goode as chief executive officer of GlucoTrack; and (ii) the appointment of Erik Emerson as chief executive officer of GlucoTrackr and as a member of the GlucoTrack Board of Directors. All other officers and directors of GlucoTrack serving immediately prior to the Effective Time continued in their respective positions.
The deal has been approved by the board of Lokahi Therapeutics Inc. and GlucoTrack, Inc., and recommend the transaction to its shareholders.
David Mannheim of Nelson Mullins Riley & Scarborough LLP acted as legal advisor for GlucoTrack, Inc. Joseph M. Lucosky and Eric Mendelson of Lucosky Brookman LLP acted as legal advisor for Lokahi Therapeutics Inc. 
